Nkarta to Participate in March Investor Conferences
Nkarta (Nasdaq: NKTX) will participate in two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference on March 2, 2026 and the Leerink Global Healthcare Conference on March 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nkarta (Nasdaq: NKTX) will participate in two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference on March 2, 2026 and the Leerink Global Healthcare Conference on March 10, 2026.
Each appearance is a fireside chat (9:10 a.m. EST on March 2; 10:40 a.m. EDT on March 10). A simultaneous webcast will be available on the company Investors site, with a replay archived for approximately 90 days.
Details
News Market Reaction – NKTX
On Feb 27, the day this news came out, NKTX closed 3.05% above the previous close.
Data tracked by StockTitan Argus for the Feb 27 session.
Key Figures
- TD Cowen conference date
- March 2, 2026
- TD Cowen 46th Annual Health Care Conference
- TD Cowen fireside time
- 9:10 a.m. EST
- Fireside chat at TD Cowen conference
- Leerink conference date
- March 10, 2026
- Leerink Global Healthcare Conference
- Leerink fireside time
- 10:40 a.m. EDT
- Fireside chat at Leerink conference
- Webcast replay duration
- 90 days
- Replay of both conference webcasts on company website
- Current share price
- $2.62
- Pre-news price context for NKTX
- 52-week range
- $1.31–$2.74
- Low and high prior to this news
- Market cap
- $183,966,436
- Equity valuation before conference announcement
Historical Context
-
Announcement of Evercore healthcare conference fireside chat with webcast and replay access.
-
Q3 2025 results with $316.5M cash, long runway, and NKX019 progress.
-
Two November 2025 healthcare conferences featuring fireside chats and webcasts.
-
ACR poster with NKX019 data showing robust CD19+ B-cell depletion and immune reset signals.
-
Announcement of H.C. Wainwright 2025 fireside chat with webcast and 90-day replay.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
natural killer (nk) cell therapies medical
autoimmune diseases medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences:
March 2, 2026
TD Cowen 46th Annual Health Care Conference
Boston, MA
9:10 a.m. EST – fireside chat
March 10, 2026
Leerink Global Healthcare Conference
Miami, FL
10:40 a.m. EDT – fireside chat
A simultaneous webcast of both events will be available on the Investors section of Nkarta’s website, and a replay will be archived on the website for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.